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Summary: Serum concentrations of lipids and apolipoprotein A-I, A-II and B were determined in patients
with hepatic metastases of colorectal cancer, with primary liver cancer and with cirrhosis.
In all three liver diseases, the HDL fraction and apolipoproteins A-I and A-II showed significantly low
values, while apolipoprotein B was only increased in hepatic metastases.
The decrease of apolipoprotein A-II levels was more prominent in cirrhosis, thereby enhancing the A-I/A-
II ratio. This ratio is decreased in metastasis and normal in hepatomas.
In patients with hepatic metastases a correlation was observed between alkaliiie phosphatase and apolipopro-
tein A-II (p < 0.05), and between -glutamyltransferase and the A-I/A-II ratio (p < 0.05).
The- present work suggests that determination of apolipoproteins and lipids of the HDL fraction offers a
new approach to the study of liver diseases.
Apolipoprotein A-I, A-II und B im Serum bei Lebermetastasen — Vergleich mit anderen Lebererkrankungen:
Hepatom und Cirrhose
Zusammenfassung: Die Konzentrationen der Lipide und der Apolipoproteine A-I, A-II und B wurden im
Serum von Patienten mit Lebermetastasen bei colorectalem Carcinom, mit primärem Lebercarcinom und
mit Cirfhosen bestimmt.
Bei allen drei Lebererkrankungen zeigten die HDL-Fraktion und die Apolipoproteine A-I und A-II signifikant
niedrige Werte, während bei Lebermetastasen allein Apolipoprotein B erhöht war.
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Der Abfall von Apolipoprotein A-II war deutlicher bei Cirrhose, wobei der A-I/A-II-Quotient erhöht war.
Dieser Quotient ist bei Metastasen erniedrigt und bei Hepatomen normal.
Bei Patienten mit Lebermetastasen wurde eine Korrelation zwischen alkalischer Phosphatase und Apolipo-
protein A-II (p < 0,05) sowie zwischen -Glutamyltransferase und dem A-I/A-II-Quotienten (p < 0,05)
beobachtet.
 f
Die vorgelegten Ergebnisse weisen darauf hin, daß die Bestimmung von Apolipoproteinen und Lipiden der
HDL-Fraktion einen neuen Zugang zur Untersuchung von Lebererkrankungen eröffnet.
Introduction
Liver cells seem to be partially involved in the syn-
thesis of apolipoproteins A-I and A-II (l, 2), the two
major polypeptides of HDL fraction (3, 4). Most
HDL molecules contain both A-I and A-II, while
some of them contain only A-I (5). The proportions
of the two apolipoproteins and the value of the A-I/
A-II ratio therefore represent clinically interesting
Parameters.
Apolipoprotein B, the major protein moiety of LDL
(6, 7) and a binding ligand for cellular receptors (8),
is also synthesized by liver or intestine (9).
The liver is the major contributor of circulating lipo-
proteins and alterations in hepatic function may influ-
ence the plasma lipoprotein profile. Several reports
(10, 11) have shown that liver diseases are charac-
terized by distinct apolipoprotein profiles: Cordova
et al. (12) and Fujii et al. (2) reported decreases of
serum apolipoprotein A-I and A-II in acute hepatitis,
cirrhosis and cholestasis.
However, the data available on apolipoprotein profi-
les in hepatomas and hepatic metastases are limited.
This study describes changes in the levels of choleste-
rol, phospholipid, total HDL and apolipoproteins
A-I, A-II and B in cases of liver metastases of colorec-
tal adenocarcinoma. These results are compared with
those obtained in two other liver deseases: hepatomas
and cirrhosis. We also investigated possible correla-
tions between the liver Status (expressed by serum -
glutamyltransferase and alkaline phosphatase cata-
lytic activities, commonly recognized äs sensitive indi-




Four populations of subjects were studied. The diagnosis of
hepatic disease was microscopically confirmed on biopsies in
all cases.
Twenty subjects suffering from hepatic metastases of cölorectal
adenocarcinoma were investigated. All patients häd been cured
of their primary carcinoma and were free from concomitant
bone involvement at the time of serum determinatiqns.
The results obtained on this group were compared with those
of three other populations:
Twenty two Senegalese black patients suffering from hepatocar-
cinomas, twenty two cases of cirrhosis without neoplastic dis-
ease and a control group including sixty-eight healthy subjects
without hepatic disorder.
Blood samples were withdrawn from all subjects after ä 12 to
14h overnight fast. Serum samples were stored for one or
two weeks frozen at -20°C with 0.05% of sodium azide.
Evaluations were made after the same time for all populations.
Analytical methods
In all populations, liver Status was investigated by the evalü-
ation of serum aspartate aminotransferase, alanine amiriotraris-
ferase, lactate dehydrogenase, alkaline phosphatase and biliru-
bin (with RÖCHE Diagnostica reagents on the Cobas-bio cen-
trifugal analyser).
Total cholesterol and total phospholipids were determined by
enzymatic methods (15, 16) on the fobas-bio analyser.
HDL-cholesterol and HDL-phospholipids were evaluated, ac-
cording to Grove et al. (17) after LDL and VLDL precipitation
by sodium phosphotungstate, MgCl2 at pH 6.15.
Determination of apolipoproteins
Apolipoproteins A-I and B were siinultaneöusly evaluated by
electro-immunodiffusion on commercially prepared agarose gel
plates (Apofilms A-I, B SEBIA) according to Fruchart et al.
(18).
Apolipoprotein A-II was evaluated by immunoturbidimetric
assay on the Cobas-bio analyser (19), using commercially
monospeciflc antisenun to human apolipoprotein A-II
purchased from Immuno-Diagnostica. The corresponding puri-
fied human apolipoprotein A-II (i. e., apolipoprotein A-II, 5.18
to 6.61 g/l) was used äs Standard and supplied äs "feference
Standard" by Immunofrance. Prior to inrniunoturbidimetric
assay the serum samples were diluted to l : 80 in a 9 g/l NaCl
solution containing 5 ml/l. Tween 20.
The apolipoprotein A-II assay was linear ovef the ränge of
0.002 to 0.011 g/l. Intra- and inter-assay coefficients of Variation
were less than 5%.
Statistical study
Comparisön of means was carried out by the Mann-Withney
U test.
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Simple linear regression analysis was performed to identify
significant (p < 0.05) relationships between apolipoprotein
levels and liver biochemical variables parameters (γ-glutamyl-
transferase, alkaline phosphatase). When necessary appropriate
log transformations were carried out to normalize distributions
and to stabilize variances.
Results
Table l summarizes the lipid profiles (total choleste-
rol, total phospholipids, cholesterol and phospholip-
ids of HDL fractions) obtained in the different popu-
lations. In liver metastases, total cholesterol is in-
creased, total phospholipid is normal, but HDL-cho-
lesterol and HDL-phospholipid are diminished (p <
0.001). Hepatomas and cirrhosis are characterized by
a decrease of all parameters.
The levels of serum apolipoproteins A-I, A-II and B
in the four populations investigated are summarized
in table 2. The mean and SD of the apolipoprotein
A-I level in healthy subjects was 1.31 ± 0.25 g/l.
In the three liver diseases, apolipoprotein A-I levels
decrease markedly (fig. l,a).
The mean and SD of the A-II level in normal subjects
was 0.44 ± 0.08 g/l. This parameter is not disturbed
in metastases, but decreases in cirrhosis (p < 0.001)
and hepatomas (p < 0.01) (fig. l,b).
The A-I/A-II ratio (2.98 ± 0.39 in normal subjects)
decreases to 1.95 ± 0.76 in metastases, is normal
in hepatomas and rises to 5.54 ± 4.26 in cirrhosis
(fig. l,c).
The apolipoprotein B levels increase in metastases
(1.39 ± 0.48 g/l) but decrease in hepatomas and
cirrhosis (fig. l,d).
The study of the correlation between liver Status and
apolipoprotein profiles shows significant correlations
between γ-glutamyltransferase and the A-I/A-II ratio,
and between alkaline phosphatase and apolipopro-
tein A-II in metastases. No relationship is noticed in
hepatomas; in cirrhosis, γ-glutamyltransferase and
alkaline phosphatase are significantly correlated with
apolipoprotein B (p < 0.01), and γ-glutamyltransfer-
ase with apolipoprotein A-II or the A-I/A-II ratio
(tab. 3).
Discussion
Since the liver is one of the major sites for the forma-
tion of apolipoproteins and lipoproteins, some, if not
most, of the pathologic events affecting this organ
ought to be reflected in changed concentrations of
plasma apolipoproteins.
Tab. 1. Comparative studies of lipid components (mean ± SD) between pathological populations and control group.
Controls n = 68
Metastases n = 20
Hepatomas n = 22





























NS = not significant, -. p < 0.05, *** = p < 0.01, **** = p < 0.001
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NS = not significant, ** = p < 0.05, *** = p < 0.01, **** = p < 0.001
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Controls Metastases Hepatomas Cirrhosis Controls Metastases Hepatomas Cirrhosis
Fig. 1. Mean ± SD of apolipoprotein A-I, A-II and B serum levels, and A-I/A-II ratio in pathological populations investigated
and of control group.
Tab. 3. Degree of linear association (r) among γ-glutamyltransferase and alkaline phosphatase with apolipoproteins and
A-I/A-II ratio in the three liver diseases.
Parameters
γ-Glutamyltransferase - Apolipoprotein A-I
Alkaline phosphatase - Apolipoprotein A-I
γ-Ghitamyltransferase - Apolipoprotein A-II
Alkaline phosphatase - Apolipoprotein A-II
γ-Glutamyltransferase - A-I/A-II
Alkaline phosphatase -A-I/A-II
γ-Glutamyltransferase - Apolipoprotein B

































In the present investigation, we attempted to elucid- The decrease of serum apolipoproteiri A-II levels in
ate the lipid abnormalities in patients with hepatic these three liver diseases seems to characterize the
metastases, giving special consideration to changes in liver Status. Nestel et al. (20) demonstrated that the
apolipoproteins compared to those occurring in two reduced concentration of apolipoprotein A-I in alco-
other liver diseases. holic hepatitis is due, not to diminished synthesis, but
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to rapid degradation. Other hypotheses have been
formulated to explain the decrease of HDL and apo-
protein in liver diseases: Luoma et al. (21, 22) showed
that in subjects with liver diseases, and a reduced
amount of healthy parenchyma, low HDL levels may
reflect impaired hepatic synthesis of HDL constitu-
ents.
An abnormal lipoprotein, apolipoprotein E-rich
HDL, was observed in patients with liver disease (23),
in patients with lecithin-cholesterol acyltransferase
deficiency (24) and in patients with alcoholic hepatitis
(25) in whom lecithin-cholesterol acyltransferase ac-
tivities are low (26, 27).
Our results show a decrease of HDL cholesterol in
the three liver diseases.
This parameter was determined after precipitation
with phosphotungstic acid/magnesium reagent which
precipitates apolipoprotein E-rich HDL (28). Conse-
quently, the HDL cholesterol levels determined in
this study did not contain this apolipoprotein E-rich
HDL.
The increase of HDL cholesterol observed by Koga
et al. (29) in patients with primary biliary cirrhosis,
may be due to the rise of apolipoprotein E-rich HDL.
These data are not in disagreement with our results,
which showed a decrease of HDL cholesterol in the
liver diseases. Elsewhere, these authors could not
detect apolipoprotein E-rich HDL in any patient with
acute viral hepatitis, alcoholic hepatitis, liver cirrhosis
or obstructive jaundice.
The simultaneous decrease of apolipoprotein A-I and
HDL cholesterol suggest that this perturbation only
affects the fraction of HDL which does not contain
apolipoprotein E. In these conditions, the decrease of
apolipoprotein A-I (activator of lecithin-cholesterol
acyltransferase), might induce a decrease of lecithin-
cholesterol acyltransferase and an increase of apoli-
poprotein E-rich HDL (26).
The apolipoprotein A-II level is markedly diminished
in cirrhosis, enhancing the interest of the A-I/A-II
ratio. In fact, this ratio is two fold increased in
cirrhosis, decreased in metastasis and normal in hepa-
tomas. As suggested by Fujji et al. (2), changes in the
relative amounts of HDL subfractions could also
account for changes in the A-I/A-II ratio, since the
ratio is greater in HDL2 than in HDL3. Possibly
decreases in HDL3 could be more prominent than
decreases in HDL2 in cirrhosis. Tateossian et al. (30)
describe a similar increase of the A-I/A-II ratio in
alcoholic cirrhosis, but the reason for the discrepan-
cies observed between cirrhosis and primary and
metastatic cancers is not elucidated.
The most distinctive feature of apolipoprotein
changes seen in patients with hepatic metastases is
the increase of apolipoprotein B levels. This rise was
also noticed by Alaupovic (10) who studied only 7
cases of hepatic metastases.
This apolipoprotein B mediates the interaction be-
tween VLDL, LDL and the apolipoprotein B, E
receptors of various cells. These receptors interact
not only with LDL containing apolipoprotein B, but
also with HDL containing apolipoprotein E (21, 22,
23, 24). It has been shown that apolipoprotein B-
and apolipoprotein E-containing lipoproteins have
similar roles in regulating intracellular cholesterol
metabolism. Thus, in patients with hepatic metastases
and microcholestasis confirmed by a correlation be-
tween alkaline phosphatase and A-II (p < 0.05), and
between γ-glutamyltransferase and the A-I/A-II ratio
(p < 0.05), it may be supposed that there is an
increase of apolipoprotein E implicated in ligand-
receptor binding, which displaces apolipoprotein B
receptor and consequently increases apolipoprotein
B levels in patients with hepatic metastases.
To elucidate this hypothesis, studies are in progress
to evaluate serum apolipoprotein E levels and their
relationship with apolipoprotein E-rich HDL.
The presented results suggest that determination of
serum apolipoproteins and lipid fractions of HDL
offers a new approach to the study of liver diseases.
In fact, they are chafacterized by low levels of the
HDL components, A-I and A-II. Apolipoprotein B
levels might be used to differentiate between cirrhosis,
hepatomas (hepatocellular dysfunction) and meta-
static liver involvement.
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